We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Resection or Vaporization Similarly Effective for BPH

By HospiMedica International staff writers
Posted on 28 Jun 2011
A new study reports that symptoms of benign prostatic hyperplasia (BPH) improve similarly well following either transurethral resection or photoselective vaporization by laser.

Researchers at Hospital Universitario Fundacion Alcorcon (Madrid, Spain) and Universidad Rey Juan Carlos (Madrid, Spain) conducted a randomized trial that compared the efficacy and safety of photoselective vaporization of the prostate (PVP) to transurethral resection of the prostate (TURP) in 100 men with symptoms of BPH. More...
International Prostate Symptom Score (IPSS), quality of life (QoL), and changes in maximum flow rate (Qmax) were the main end points. Patients were evaluated at a follow-up time of two years; during this time, five patients were lost to follow-up. A last observation was used to establish carried forward analysis.

The results showed that both laser PVP and TURP resulted in the same IPPS reduction at two years, and in the same gain in Qmax; QoL was equivalent for both treatment modalities. These results were independent of prostate size, risk category, and prior indwelling catheter. No statistically significant differences were detected between arms in terms of complication rates, but in-hospital stay and time to catheter removal were significantly shorter with PVP. In the laser PVP group, three patients were readmitted to the hospital and two developed a urethral stricture. In the TURP group, two patients were readmitted, six developed a urethral stricture, and two developed bladder neck sclerosis. The study was published online on June 1, 2011, in European Urology.

"This is the second randomized clinical trial performed to date on the efficacy of the GreenLight HPS 120-W laser compared with transurethral resection of the prostate," concluded lead author Carlos Capitan, MD, and colleagues of the department of urology. "Results show the same efficacy for International Prostate Symptom Score reduction and maximum flow rate increase with shorter length of stay for laser photoselective vaporization of the prostate."

The GreenLight HPS Laser System, a product of American Medical Systems (Minnetonka, MN, USA), combines a 532-nm wavelength with advanced laser technology, allowing highly selective absorption in tissue hemoglobin, unimpeded by the procedural irrigant. Depth of tissue coagulation, irrespective of the power level utilized, does not exceed 1 mm - 2 mm, since most of the thermal energy is both consumed and carried away by the highly efficient vaporization effect.

Related Links:

Hospital Universitario Fundacion Alcorcon
Universidad Rey Juan Carlos
American Medical Systems




Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Pressure Guidewire
SavvyWire
Ultrasound Needle Guidance System
SonoSite L25
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.